Abstract
Rituximab, a chimeric anti-CD20 monoclonal antibody, is used to treat rheumatologic and hematologic diseases. Serum sickness, a Type III delayed hypersensitivity reaction, has been reported with rituximab treatment. Traditionally, drug desensitization has been used to treat Type I IgE-mediated hypersensitivity reactions. We report the first case of successful drug desensitization to rituximab in a patient with medication-induced serum sickness. In our case, a 37-year-old woman with Sjogren’s syndrome and papillary thyroid carcinoma developed serum sickness 72 hours following rituximab infusion for gastric mucosal associated lymphoma tissue (MALT). Her MALT progressed after stopping rituximab. She underwent a rapid 12-step intravenous rituximab desensitization without recurrence of serum sickness. Following the completion of 4 rituximab desensitizations, she had gastric MALT remission. She received 25 maintenance rituximab doses using this desensitization protocol quarterly without complications. This is the first report documenting rituximab desensitization for the treatment of delayed drug reactions like serum sickness.
Keywords: Desensitization, hypersensitivity, mucosa associated lymphoid tissue, rituximab, serum sickness.
Current Drug Safety
Title:Desensitization Protocol for Rituximab-Induced Serum Sickness
Volume: 9 Issue: 3
Author(s): Merritt L. Fajt and Andrej A. Petrov
Affiliation:
Keywords: Desensitization, hypersensitivity, mucosa associated lymphoid tissue, rituximab, serum sickness.
Abstract: Rituximab, a chimeric anti-CD20 monoclonal antibody, is used to treat rheumatologic and hematologic diseases. Serum sickness, a Type III delayed hypersensitivity reaction, has been reported with rituximab treatment. Traditionally, drug desensitization has been used to treat Type I IgE-mediated hypersensitivity reactions. We report the first case of successful drug desensitization to rituximab in a patient with medication-induced serum sickness. In our case, a 37-year-old woman with Sjogren’s syndrome and papillary thyroid carcinoma developed serum sickness 72 hours following rituximab infusion for gastric mucosal associated lymphoma tissue (MALT). Her MALT progressed after stopping rituximab. She underwent a rapid 12-step intravenous rituximab desensitization without recurrence of serum sickness. Following the completion of 4 rituximab desensitizations, she had gastric MALT remission. She received 25 maintenance rituximab doses using this desensitization protocol quarterly without complications. This is the first report documenting rituximab desensitization for the treatment of delayed drug reactions like serum sickness.
Export Options
About this article
Cite this article as:
Fajt L. Merritt and Petrov A. Andrej, Desensitization Protocol for Rituximab-Induced Serum Sickness, Current Drug Safety 2014; 9 (3) . https://dx.doi.org/10.2174/1574886309666140509154056
DOI https://dx.doi.org/10.2174/1574886309666140509154056 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Update on the Management of Severe Cutaneous Drug Hypersensitivity Reactions
Current Pharmaceutical Design The Forward Path for Biopharmaceuticals and Biosimilars: Emerging Options in the Selection of Host Cell Systems
Current Biotechnology Complement Activation-Related Pseudoallergy Caused by Amphiphilic Drug Carriers: The Role of Lipoproteins
Current Drug Delivery Efficacy of Montelukast as Added Therapy in Patients with Chronic Idiopathic Urticaria
Inflammation & Allergy - Drug Targets (Discontinued) Modeling Anti-Allergic Natural Compounds by Molecular Topology
Combinatorial Chemistry & High Throughput Screening Immunotherapy in Allergies: An Update
Inflammation & Allergy - Drug Targets (Discontinued) Treatment for Diabetic Peripheral Neuropathy: What have we Learned from Animal Models?
Current Diabetes Reviews Neprilysin: A Potential Therapeutic Target of Arterial Hypertension?
Current Cardiology Reviews C1-Inhibitor: Structure, Functional Diversity and Therapeutic Development
Current Medicinal Chemistry Spontaneous (Autoimmune) Chronic Urticaria in Children: Current Evidences, Diagnostic Pitfalls and Therapeutic Management
Recent Patents on Inflammation & Allergy Drug Discovery Could Additional Inhibitors of the Renin -Angiotensin System be Clinically Useful?
Current Hypertension Reviews Perception of Symptoms in Hypertensive Patients and the Relevance to the Application of Anti- Hypertensive Drug Therapy
Current Pharmaceutical Design Hypersensitivity to Hymenoptera Venom: Advances in Diagnosis and Implications for Treatment
Recent Patents on Inflammation & Allergy Drug Discovery Pharmacotherapy for Smoking Cessation: Present and Future
Current Pharmaceutical Design A Multicenter Study of IgE Sensitization to <i>Anisakis simplex</i> and Diet Recommendations
Endocrine, Metabolic & Immune Disorders - Drug Targets Understanding and Avoiding Antiretroviral Adverse Events
Current Pharmaceutical Design Prevention of Macrovascular Disease in Type 2 Diabetic Patients: Blockade of the Renin-Angiotensin-Aldosterone System
Current Diabetes Reviews New Ways of Detecting ADRs in Neonates and Children
Current Pharmaceutical Design Acute and Long-Term Effects of Cannabis Use: A Review
Current Pharmaceutical Design Current and Future Chemotherapy for Chagas Disease
Current Medicinal Chemistry